Condition: Genetic Testing · BRCA1/2 · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to describe how women with BRCA1/2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.
This description comes directly from the study's public registry record.
Jada Hamilton, PhD, MPH · 646-888-0049 · hamiltoj@mskcc.org
Mark Robson, MD · 646-888-5486
Always discuss trial participation with your own doctor first.
| Dana Farber Cancer Institute (Data Collection Only) | Boston, Massachusetts, United States | Recruiting |
| Memorial Sloan-Kettering at Basking Ridge | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Commack | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau | Uniondale, New York, United States | Recruiting |
| Abramson Cancer Center at University of Pennsylvania Medical Center (Data Collection Only) | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03396341